Item 1.01 Entry into a Material Definitive Agreement.
Merger Agreement
On
Consideration and Structure
Under the Merger Agreement, the Company has agreed to acquire all of the outstanding equity interests of Gemini in exchange for 21,500,000 shares of Company Class A common stock, subject to adjustments, to be paid at the effective time of the Merger.
Pursuant to the Merger Agreement, at or prior to the effective time of the Merger, each option exercisable for Gemini equity that is outstanding immediately prior to the effective time of the Merger shall be assumed by the Company and continue in full force and effect on the same terms and conditions as are currently applicable to such options, subject to adjustments to exercise price and number of shares of Company Class A common stock issued upon exercise. In addition, the Merger Agreement contemplates that at Closing, the Company will deliver 2,150,000 of its shares of Class A common stock to be placed into escrow for indemnification purposes, as further described in the Merger Agreement.
Representations, Warranties and Covenants
The parties to the Merger Agreement have agreed to customary representations and warranties for transactions of this type. The representations and warranties of Gemini made under the Merger Agreement will survive until twelve (12) months following the Closing. In addition, the parties to the Merger Agreement agreed to be bound by certain customary covenants for transactions of this type, including, among others, covenants with respect to the conduct of Gemini, the Company and their respective subsidiaries during the period between execution of the Merger Agreement and the Closing. The covenants made under the Merger Agreement will not survive the Closing. Each of the parties to the Merger Agreement has agreed to use its reasonable best efforts to cause all actions and things necessary to consummate and expeditiously implement the Merger.
1 Conditions to Closing
Under the Merger Agreement, the obligations of the parties to consummate the
Merger are subject to the satisfaction or waiver of certain customary closing
conditions of the respective parties, including, without limitation: (i) the
approval and adoption of the Merger Agreement and transactions contemplated
thereby by requisite vote of the Company's stockholders (the "Company
Stockholder Approval") and the Gemini's stockholders (the "Gemini Stockholder
Approval"); (ii) the receipt of consents or approvals from the applicable
governmental, regulatory or administrative authorities; (iii) the aggregate cash
proceeds from Company's trust account, together with the proceeds from the
Subscriptions (as defined below), equaling no less than
Termination
The Merger Agreement may be terminated under certain customary and limited
circumstances at any time prior to the Closing, including, without limitation,
(i) by the Company or Gemini, if (A) the Closing has not occurred by
Item 3.02 Unregistered Sales of
The disclosure set forth above in Item 1.01 of this Current Report with respect to the issuance of the Company's common stock in connection with the transactions contemplated by the Merger Agreement and the Subscription Agreements is incorporated by reference herein. The common stock issuable pursuant to the Subscription Agreements will not be registered under the Securities Act of 1933, as amended (the "Securities Act"), in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act.
Item 7.01 Regulation FD Disclosure.
On
Furnished as Exhibit 99.2 hereto is the investor presentation that will be used by the Company in connection with the Merger.
The information in this Item 7.01 and Exhibits 99.1 and 99.2 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 8.01 Other Events. Voting Agreement
In connection with the Closing,
The foregoing description of the Voting Agreement does not purport to be complete and is qualified in its entirety by the terms and conditions of the Voting Agreement, a form of which is attached as Exhibit D to the Merger Agreement.
Registration Rights Agreement
In connection with the Closing, the Company, and Gemini, and certain of their respective stockholders will enter into a registration rights agreement (the "Registration Rights Agreement"). Pursuant to the Registration Rights Agreement, New Gemini will be required to register for resale securities held by the stockholders party thereto. In addition, the holders will have certain demand and "piggyback" registration rights. New Gemini will bear the expenses incurred in connection with the filing of any registration statements pursuant to the Registration Rights Agreement. The Registration Rights Agreement will also restrict the ability of each stockholder who is a party thereto to transfer its shares of New Gemini common stock for a period of one hundred eighty (180) days following the Closing, subject to certain permitted transfers.
The foregoing description of the Registration Rights Agreement does not purport to be complete and is qualified in its entirety by the terms and conditions of the Registration Rights Agreement, a form of which is attached as Exhibit F to the Merger Agreement.
4
Important Information About the Merger and Where to Find It
A full description of the terms of the business combination will be provided in
a registration statement on Form S-4 to be filed with the
Participants in the Solicitation
The Company and Gemini and their respective directors and executive officers may
be considered participants in the solicitation of proxies with respect to the
proposed business combination described in this Current Report under the rules
of the
Forward-Looking Statements
This Current Report contains forward-looking statements that are based on
beliefs and assumptions and on information currently available. In some cases,
you can identify forward-looking statements by the following words: "may,"
"will," "could," "would," "should," "expect," "intend," "plan," "anticipate,"
"believe," "estimate," "predict," "project," "potential," "continue," "ongoing"
or the negative of these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements involve risks,
uncertainties and other factors that may cause actual results, levels of
activity, performance or achievements to be materially different from the
information expressed or implied by these forward-looking statements. Although
we believe that we have a reasonable basis for each forward-looking statement
contained in this Current Report, we caution you that these statements are based
on a combination of facts and factors currently known by us and our projections
of the future, about which we cannot be certain. Forward-looking statements in
this Current Report include, but are not limited to, statements regarding the
proposed business combination, including the timing and structure of the
business combination, the proceeds of the business combination, the initial
market capitalization of the New Gemini and the benefits of the business
combination, as well as statements about the potential attributes and benefits
of Gemini's product candidates and the format and timing of Gemini's product
development activities and clinical trials. We cannot assure you that the
forward-looking statements in this Current Report will prove to be accurate.
These forward-looking statements are subject to a number of significant risks
and uncertainties that could cause actual results to differ materially from
expected results, including, among others, the ability to complete the business
combination due to the failure to obtain approval from the Company's
shareholders or satisfy other closing conditions in the Merger Agreement, the
occurrence of any event that could give rise to the termination of the Merger
Agreement, the ability to recognize the anticipated benefits of the business
combination, the outcome of any legal proceedings that may be instituted against
the Company or Gemini following announcement of the proposed business
combination and related transactions, the impact of COVID-19 on Gemini's
business and/or the ability of the parties to complete the business combination,
the ability to obtain or maintain the listing of the Company's common stock on
Nasdaq following the proposed business combination, costs related to the
proposed business combination, changes in applicable laws or regulations, the
possibility that the Company or Gemini may be adversely affected by other
economic, business, and/or competitive factors. and other risks and
uncertainties, including those to be included under the header "Risk Factors" in
the registration statement on Form S-4 to be filed by the Company with the
5
No Offer or Solicitation
This Current Report is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed business combination and shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits Exhibit No. Description 99.1 Press Release, datedOctober 15, 2020 . 99.2 Investor Presentation. 6
© Edgar Online, source